{"id":196847,"date":"2024-10-01T03:22:43","date_gmt":"2024-10-01T08:22:43","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/10\/new-therapy-for-glioma-receives-fda-approval"},"modified":"2024-10-01T03:22:43","modified_gmt":"2024-10-01T08:22:43","slug":"new-therapy-for-glioma-receives-fda-approval","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/10\/new-therapy-for-glioma-receives-fda-approval","title":{"rendered":"New therapy for glioma receives FDA approval"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-therapy-for-glioma-receives-fda-approval2.jpg\"><\/a><\/p>\n<p>The FDA has approved a new targeted drug specifically for brain tumors called low-grade gliomas. The drug, vorasidenib, was shown in clinical trials to delay progression of low-grade gliomas that had mutations in the IDH1 or IDH2 genes.<\/p>\n<p>\u201cAlthough there have been other targeted therapies for the treatment of brain tumors with the IDH mutation, [this one] has been one of the most successful in survival prolongation of brain tumor patients,\u201d said <a href=\"https:\/\/neurosurgery.duke.edu\/profile\/darell-doty-bigner\">Darell Bigner, MD, PhD,<\/a> the E. L. and Lucille F. Jones Cancer Distinguished Research Professor and founding director of the <a href=\"https:\/\/tischbraintumorcenter.duke.edu\/\">Preston Robert Tisch Brain Tumor Center at Duke.<\/a><\/p>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2304194\" target=\"_blank\">In clinical trials<\/a>, progression-free survival was estimated to be 27.7 months for people in the vorasidenib group versus 11.1 months for those in the placebo group.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved a new targeted drug specifically for brain tumors called low-grade gliomas. The drug, vorasidenib, was shown in clinical trials to delay progression of low-grade gliomas that had mutations in the IDH1 or IDH2 genes. \u201cAlthough there have been other targeted therapies for the treatment of brain tumors with the IDH mutation, [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412,47],"tags":[],"class_list":["post-196847","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/196847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=196847"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/196847\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=196847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=196847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=196847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}